Value-based medicine: Evidence-based medicine and beyond

被引:25
作者
Brown, GC
Brown, MM
Sharma, S
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA
[2] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[3] Queens Med Coll, Ctr Ocular Cost Effect Hlth Policy, Kingston, ON, Canada
关键词
value-based medicine; cost-utility analysis; evidence-based medicine;
D O I
10.1076/ocii.11.3.157.17355
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Value-based medicine is the practice of medicine emphasizing the value received from an intervention. Value is measured by objectively quantifying: 1) the improvement in quality of life and/or 2) the improvement in length of life conferred by an intervention. Evidence-based medicine often measures the improvement gained in length of life, but generally ignores the importance of quality of life improvement or loss. Value-based medicine incorporates the best features of evidence-based medicine and takes evidence-based data to a higher level by incorporating the quality of life perceptions of patients with a disease in concerning the value of an intervention. Inherent in value-based medicine are the costs associated with an intervention. The resources expended for the value gained in value-based medicine is measured with cost-utility analysis in terms of the $/QALY (money spent per quality-adjusted life-year gained). A review of the current status and the likely future of value-based medicine is addressed herein.
引用
收藏
页码:157 / 170
页数:14
相关论文
共 57 条
[1]  
[Anonymous], 1991, Arch Ophthalmol, V109, P1109
[2]   The death of cost-minimization analysis? [J].
Briggs, AH ;
O'Brien, BJ .
HEALTH ECONOMICS, 2001, 10 (02) :179-184
[3]  
Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
[4]  
Brown G C, 2000, Qual Manag Health Care, V9, P23
[5]   Cost-effectiveness of treatment for threshold retinopathy of prematurity [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Tasman, W ;
Brown, HC .
PEDIATRICS, 1999, 104 (04) :e47
[6]   Quality of life associated with diabetes mellitus in an adult population [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Brown, H ;
Gozum, M ;
Denton, P .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2000, 14 (01) :18-24
[7]  
Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
[8]   Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Busbee, B ;
Brown, H .
OPHTHALMIC EPIDEMIOLOGY, 2002, 9 (01) :1-10
[9]   A cost-utility analysis of interventions for severe proliferative vitreoretinopathy [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Busbee, B ;
Landy, J .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2002, 133 (03) :365-372
[10]   Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Busbee, B ;
Brown, H .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2000, 20 (04) :331-337